Association of anti‐factor Xa‐guided anticoagulation with hemorrhage during ECMO support: A systematic review and meta‐analysis
Clinical Cardiology · 2024-05 · 47 (5)
DOI: 10.1002/clc.24273 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Cardiology, online erschienen am 02.05.2024. Verfasst von Sasa Rajsic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Hemorrhage, Factor Xa Inhibitors, Anticoagulants. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The use of extracorporeal membrane oxygenation (ECMO) is associated with complex hemostatic changes. Systemic anticoagulation is initiated to prevent clotting in the ECMO system, but this comes with an increased risk of bleeding. Evidence on the use of anti‐Xa‐guided monitoring to prevent bleeding during ECMO support is limited. Therefore, we aimed to analyze the association between anti‐factor Xa‐guided anticoagulation and hemorrhage during ECMO.
Methods
A systematic review and meta‐analysis was performed (up to August 2023). PROSPERO: CRD42023448888.
Results
Twenty‐six studies comprising 2293 patients were included in the analysis, with six works being part of the meta‐analysis. The mean anti‐Xa values did not show a significant difference between patients with and without hemorrhage (standardized mean difference −0.05; 95% confidence interval [CI]: −0.19; 0.28, p = .69). We found a positive correlation between anti‐Xa levels and unfractionated heparin dose (UFH; pooled estimate of correlation coefficients 0.44; 95% CI: 0.33; 0.55, p < .001). The most frequent complications were any type of hemorrhage (pooled 36%) and thrombosis (33%). Nearly half of the critically ill patients did not survive to hospital discharge (47%).
Conclusions
The most appropriate tool for anticoagulation monitoring in ECMO patients is uncertain. Our analysis did not reveal a significant difference in anti‐Xa levels in patients with and without hemorrhagic events. However, we found a moderate correlation between anti‐Xa and the UFH dose, supporting its utilization in monitoring UFH anticoagulation. Given the limitations of time‐guided monitoring methods, the role of anti‐Xa is promising and further research is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria.
- Anesthesia and Intensive Care Department, Pain Therapy Service, Cagliari University, Cagliari, Italy.
- Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Zitieren
APA
Rajsic, S., Breitkopf, R., Treml, B., Jadzic, D., Innerhofer, N., Eckhardt, C., Oberleitner, C., & Bukumiric, Z. (2024). Association of anti‐factor Xa‐guided anticoagulation with hemorrhage during ECMO support: A systematic review and meta‐analysis. Clinical Cardiology, 47(5). https://doi.org/10.1002/clc.24273
Vancouver
Rajsic S, Breitkopf R, Treml B, Jadzic D, Innerhofer N, Eckhardt C, et al. Association of anti‐factor Xa‐guided anticoagulation with hemorrhage during ECMO support: A systematic review and meta‐analysis. Clinical Cardiology. 2024;47(5). doi:10.1002/clc.24273
BibTeX
@article{Rajsic2024,
author = {Rajsic, Sasa and Breitkopf, Robert and Treml, Benedikt and Jadzic, Dragana and Innerhofer, Nicole and Eckhardt, Christine and Oberleitner, Christoph and Bukumiric, Zoran},
title = {Association of anti‐factor Xa‐guided anticoagulation with hemorrhage during ECMO support: A systematic review and meta‐analysis},
journal = {Clinical Cardiology},
year = {2024},
volume = {47},
number = {5},
doi = {10.1002/clc.24273}
}
EUVIMED